Drug Hunter
Gary Yeung, CFA is a life science executive (President, COO, CFO, and CBO), board member, advisor, and investor with extensive strategy, finance, business development, and operations experience in forming and building biotech companies and developing novel therapies.
Gary has raised over $570M ($370M as CFO and $200M as an advisor and board member) while forming and building multiple successful biotech companies: Xilis, Erasca (NASDAQ: ERAS), NiKang, Guardant Health (NASDAQ: GH), and Annexon Biosciences (NASDAQ: ANNX). He has led organizations engaged in filing 42 INDs, and led teams that launched multiple FDA-approved treatments at Genentech. Earlier in his career, he worked in management consulting at McKinsey and operations leadership at GE.
Gary holds a B.S. in Chemical Engineering from the University of California, Berkeley and an MBA from University of California, Los Angeles. He is a Chartered Financial Analyst (CFA).
This person is not in the org chart
This person is not in any offices
Drug Hunter
Drug Hunter is a dependable, impartial source of fact-checked information for the community of drug researchers. Professionals involved in drug discovery can use it to save time, keep updated, and generate ideas. The biotech and pharmaceutical sectors, in addition to the research and individuals that work in them, are celebrated by them. They maylocate new partners, drug discovery activities, professional opportunities, and other resources. They collaborate with companies that have creative innovations and beneficial materials to offer R&D executives.